Contineum Therapeutics (CTNM) Competitors $12.44 -0.04 (-0.32%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CTNM vs. NRIX, KNSA, RCUS, OCUL, MRVI, ARVN, PRAX, CALT, DAWN, and ANIPShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Ocular Therapeutix (OCUL), Maravai LifeSciences (MRVI), Arvinas (ARVN), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Nurix Therapeutics Kiniksa Pharmaceuticals Arcus Biosciences Ocular Therapeutix Maravai LifeSciences Arvinas Praxis Precision Medicines Calliditas Therapeutics AB (publ) Day One Biopharmaceuticals ANI Pharmaceuticals Nurix Therapeutics (NASDAQ:NRIX) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, community ranking, institutional ownership, risk, valuation, analyst recommendations and earnings. Do analysts rate NRIX or CTNM? Nurix Therapeutics currently has a consensus price target of $30.35, suggesting a potential upside of 58.58%. Contineum Therapeutics has a consensus price target of $29.25, suggesting a potential upside of 135.13%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.94Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community favor NRIX or CTNM? Nurix Therapeutics received 67 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 78.95% of users gave Nurix Therapeutics an outperform vote. CompanyUnderperformOutperformNurix TherapeuticsOutperform Votes7578.95% Underperform Votes2021.05% Contineum TherapeuticsOutperform Votes8100.00% Underperform VotesNo Votes Does the media refer more to NRIX or CTNM? In the previous week, Nurix Therapeutics had 3 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Nurix Therapeutics and 0 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.00 beat Nurix Therapeutics' score of -0.11 indicating that Contineum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Nurix Therapeutics Neutral Contineum Therapeutics Neutral Which has stronger earnings & valuation, NRIX or CTNM? Contineum Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$76.99M17.61-$143.95M-$2.91-6.58Contineum Therapeutics$50M6.41$22.72MN/AN/A Is NRIX or CTNM more profitable? Contineum Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -313.65%. Contineum Therapeutics' return on equity of -49.92% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-313.65% -63.39% -41.82% Contineum Therapeutics N/A -49.92%-20.52% SummaryContineum Therapeutics beats Nurix Therapeutics on 9 of the 14 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$320.68M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.9189.4217.36Price / Sales6.41309.211,240.0477.11Price / Cash10.6861.4443.7535.97Price / Book-3.346.055.314.79Net Income$22.72M$154.90M$122.54M$225.00M7 Day Performance-2.58%1.35%1.42%2.37%1 Month Performance-7.85%0.41%2.51%4.40%1 Year PerformanceN/A3.08%25.29%20.10% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics1.4258 of 5 stars$12.44-0.3%$29.25+135.1%N/A$320.68M$50M0.0031NRIXNurix Therapeutics2.1583 of 5 stars$19.01+4.2%$30.35+59.7%+134.6%$1.35B$56.42M-6.53300KNSAKiniksa Pharmaceuticals2.9387 of 5 stars$18.17-8.8%$36.60+101.4%-1.8%$1.31B$384.10M-129.78220Gap DownRCUSArcus Biosciences1.8822 of 5 stars$13.98-1.5%$34.00+143.2%-8.8%$1.28B$263M-4.44500OCULOcular Therapeutix3.6583 of 5 stars$8.12-1.1%$16.71+105.8%+108.1%$1.28B$61.44M-6.15230Gap DownMRVIMaravai LifeSciences4.6304 of 5 stars$4.93+1.6%$10.28+108.5%-23.7%$1.24B$276.92M-3.01610ARVNArvinas2.5306 of 5 stars$18.01-3.3%$63.50+252.6%-50.4%$1.24B$161.10M-3.86420PRAXPraxis Precision Medicines1.8965 of 5 stars$64.02+1.4%$146.33+128.6%+88.5%$1.19B$1.61M-6.22110CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180DAWNDay One Biopharmaceuticals1.9964 of 5 stars$11.56-2.0%$35.86+210.2%-9.9%$1.17BN/A-11.2260News CoverageHigh Trading VolumeANIPANI Pharmaceuticals4.474 of 5 stars$53.93-2.0%$77.71+44.1%+5.5%$1.13B$555.46M-98.05600Short Interest ↓Gap DownHigh Trading Volume Related Companies and Tools Related Companies NRIX Competitors KNSA Competitors RCUS Competitors OCUL Competitors MRVI Competitors ARVN Competitors PRAX Competitors CALT Competitors DAWN Competitors ANIP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTNM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTNM Stock Alerts